Arch Pharmalabs Unlisted Share Price Pre IPO – Buy / Sell Now
Last Updated Date: Feb 17, 2023We got everything in line with the Arch Pharmalabs unlisted shares / Pre IPO, and have compiled everything in this particular article. We present to you, every other detail of the company to best facilitate your research and investment plan.
Management | Trustworthy |
Accounting Practice | Clean |
Profitability | Outstanding |
Financial Solvency | Exceed Expectations with the present round of Fundings |
Business Growth | Outstanding |
Valuation | Overvalued |
Market Position | Dominant leader |
Overall Rating | 5 Star |
Recommendation | Buy |
The pre IPO stock industry is a major source for investment, and willing to explore it, you can study this particular company. Know about the management, the company insights, account practice, the financial stature, and more via this write-up.
Also, you get to know about the company share details via this article. You can check out the present price and also the future expected price of the shares, and then make an investment call.
Arch Pharmalabs Unlisted Share – Review
Let us get you started with the review of the company on basic grounds. So, a basic insight on the company, from all angles is provided in this article. You can refer to them all, and see how profitable these investment options are.
Reg Date | 02-Apr-93 |
ISIN | INE182F01017 |
Sector | Pharmaceutical |
Sub-Sector | Manufacturing (Chemicals and chemical products) |
Current Price | Rs. 90-95 |
Total Income | Rs. 651.50 Cr. |
Market Capital | NA |
Profit after Tax | Rs. -159.50 Cr. |
Total shares | NA |
Starting right from management information, we have included the kind of account practice the company adopts. Everything is briefed in the best form, i.e. tabular representation, for you to grasp hold of the information soon enough.
Further insights are compiled in the next sections of the article, and you can absorb all the information you need about this investment option.
Arch Pharmalabs Unlisted Share – Evaluation
We have taken notes of the financial aspects of the company, and this includes the majority of the ratios. Such ratios let you study the company on the whole, from all aspects and let you determine the future of the company and your investment combined.
Intrinsic Value | NA |
Total Equity | NA |
Total Revenue | NA |
Return on Equity | NA |
CFO | NA |
CMP | Rs. |
Face Value | Rs.10 |
Basic EPS | Rs.15.19 Cr |
Dividend Yield | NA |
D/E | -2.82 |
Earnings Yield | NA |
P/E Ratio | NA |
EBITDA | NA |
EV / EBITDA | NA |
Capital Adequacy Ratio | NA |
ROE, EPS, CMP, Dividend Yield, EBITDA, Earning yield, and more are some of the ratios and figures you need to know about. We have added them all in the tables you see in this article, for you to refer to them instantly.
Carry out the process of fundamental analysis which is a major game-changer and often your means to end, the process of decision making.
To Buy/Sell Unlisted Shares. Fill up this Form.
About Arch Pharmalabs Limited
The company was registered in the year 1993 and belongs to the sector of pharmaceuticals. It is into the manufacturing process of chemicals and chemical products, and relatable services as well.
Precisely, they are into the manufacturing and sale of APIs and Intermediates to innovators and generic pharmaceutical players. Markets they ventured into comprise both Domestic and International markets along with the regulated markets.
As per the present stature of the company, they have 8 manufacturing facilities. Every facility has separate and specific use while the reactor capacity is around 1200 KL. They precisely have 3 business verticals, of which we speak in the following section.
Arch Pharmalabs Unlisted Share – Products/Services
The company manufactures a variety of APIs and Intermediates using a combination of processes. All of this is done in the 8 manufacturing facilities they own, which they have expanded efficiently, over the period of time. Here are their three business verticals –
- API Manufacturing – Under this vertical, the team, irrespective of the organizational and geographic boundaries, cater to the need of their clients. All the changing API needs of their clients are looked upon.
- Intermediate Manufacturing – The company manufactures Intermediates while ensuring they are properly equipped with proper effluent treatment and solvent recovery systems. Regulatory requirements are not overlooked as well.
- Contract Services – This company has expanded its strategic alliances and co-marketing agreements, as a result of which manufacturing strength as well shot up.
Check out other Major Unlisted Shares here
Arch Pharmalabs Unlisted Share – Current Asset Count
The balance sheet often the parameter which lets you check out the stature of the debt and equity the company holds. The funds gathered by the company and retained are clearly portrayed in the balance sheet and you need to check it out.
We have access to the information from the year 2019 as well as 2020, regarding the assets count of the company. The non-current asset of the company account for Rs.22706.68 lakhs in the year 2020 and 22729.43 lakhs in the year 2019.
On the other front, the current assets were Rs.179731.72 lakhs in the year 2020 and Rs.186124.052 lakhs in 2019.
Arch Pharmalabs – Planned Investments
As we have already mentioned, the company has made significant investments in the domain of facilities it owns. It has successfully expanded to 8 facilities, all of which render to the manufacturing process of the company.
The need to manufacture and sell API and intermediaries, complying with the norms is fulfilled by its manufacturing facilities. The facilities have the capacity to meet the needs of their clients irrespective of the change in need.
They have maintained proper effluent treatment and solvent recovery systems at all times, to fulfill the need of their clients efficiently.
Arch Pharmalabs – Sector & Revenue Status
API and its intermediates market are boosting with the rapid R&D in the sector. The market leaders are taking the bars high, making the sector highly valued in multiple terms. Arch Pharmalabs revenue from the years would portray the competition and market stature.
Checking up the revenue, this company is presently not up to the mark with the sector or industry. The company has been incurring heavy losses for a bunch of years and this is not a positive side of the company.
The exact loss the company has incurred is provided to you in the following sub-sections.
Arch Pharmalabs – Various Divisions & Subordinate
Arch Pharmalabs is into the business of manufacturing and selling API and its intermediates to national as well as international clients.
Clients can avail themselves of contract manufacturing, custom synthesis, and contract research services comprising route selection, process development, optimization, analytical development, stability studies, safety studies, scale up to technology transfer, clinical trial manufacturing, and commercial manufacturing from them.
Also, in the year 2007 Arch Pharmalabs Ltd acquired Hyderabad-based Watsol Organics Ltd., a manufacturer of pharmaceuticals and agro-chemical intermediates.
Arch Pharmalabs Pre IPO Industry at a glance
API or the Active pharmaceutical ingredients and API intermediates are set to rise at a projected high rate, in the near 5 years. The projected rate is of a growth of CAGR 7.17% in the provided time interval.
The expectation in the rise is on account of high chronic diseases, technology advances in API manufacturing, and increasing generic significance.
The major players of the market from the world have showcased certain developments in the active pharmaceutical ingredients or API market. Constant additions were witnessed in the year 2018, which has led to the present and the future projected growth of the market.
Arch Pharmalabs – Enterprise Potential
Presently, the financial reports of the company show a negative side of the company, as it lags. The financials of the company are not strong enough from the past few years, as the company is incurring heavy losses year after year.
The loss incurred has only been on a hike as it was Rs.61.14 Cr in the year 2018, Rs.131.31 Cr in the year 2019, and Rs.159.50 Cr in the year 2020. As a result of this, the EPS and net worth of the company as well fell up to become negative.
You need to study the company in dept to see if there is an exceeding potential portrayed by the company, for future growth.
Arch Pharmalabs Unlisted Shares – Overall Counsel
To Buy/Sell Unlisted Shares. Fill up this Form.
Arch Pharmalabs Stocks – Financial Statement
Financial statements are a must to check, and herein we have included the insights of the 2 most crucial financial statements. You can check up on the balance sheet as well as the profit and loss account of the company, which are mentioned below.
Balance Sheet
Total assets, as well as Total Liabilities and equity for the year 2020, Stood at Rs.302792.36 lakhs. On the other hand, the figure was Rs.315003.45 lakhs in the year 2019.
You can furthermore check the current assets and liabilities, non-current assets and liabilities as well as shareholder’s fund’s information in the annual report’s links of the company. It contains the balance sheet as and when drafted by the company.
Profit and Loss Account
Statement of profit and loss is as well included in the annual links provided in the next section. However, here are the basic insights into the company’s financial statement.
Total revenue for the year 2019 was Rs.51477.75 lakhs which was less than the revenue of Rs.65150.33 lakhs made in the year 2020. However, the company has constantly incurred losses for both years. Loss for the year 2019 was Rs.13,110.77 lakhs, and it was Rs.16,019.07 lakhs in 2020.
Arch Pharmalabs – Company Address
The current registered office of Arch Pharmalabs is:
Reg Office | 3rd Floor, Titanic Building, Chandivali Farm Road, Nr. HDFC Bank, Andheri (East) Mumbai Mumbai City – 400072 Maharashtra – India |
Website | Arch Pharmalabs Website Link |
Arch Pharmalabs – Managerial Personnel
Below are the current key managerial personnel of the company:
- Raj Kumar Rishi (Managing Director)
- David Brian Dyas (Director)
- Prakash Kulathu Iyer (Independent Director)
- Rishi Kant Srivastava (Independent Director)
- Rodney Noonoo (Director)
- Ashraf M.A. Elarman (Director)
- Lisa Marie Oliver (Director)
Arch Pharmalabs – Annual Report Links
FAQ on Arch Pharmalabs Unlisted Share
Can I buy Arch Pharmalabs Pre IPO shares?
You can choose to go get in touch with your stock broker or local bankers regarding Unlisted shares investment. If you are enthusiastic about investing in Arch Pharmalabs shares that are not listed in centralized exchanges, you sure can buy them via other intermediaries.
Is Arch Pharmalabs Pre-IPO investing good?
Strategic form of investment alike listed shares investment is crucial. Herein, you need to check for the company’s financials and keep a frequent check on its news and recent changes. We would also provide you a heads-up on the same by giving you the best price of companies’ unlisted shares. Check Snapshot, Company reputation, Industry Experience, management performance, and more.
How do I buy Arch Pharmalabs unlisted shares?
There are multiple ways in which you can take a buying step of Arch Pharmalabs Pre-IPO Stock. Search for the brokers and dealers who deal in the Over-The-Counter market. Get in touch with Top10stockbroker or visit the website to check for the latest Deals. Furthermore, you can Fill-up the contact form with your details and we will get back to you as soon as possible.
How do you value Arch Pharmalabs pre-IPO stocks?
One of the multiple Arch Pharmalabs Pre-IPO Shares valuation methods is finding the FMV or Fair Market Value. You can use the discounted cash flow method or the book value method to encounter a close to the value of the stocks. Furthermore, you can attempt a comparative analysis of the said shares from multiple stock broker’s websites.
How do I sell Arch Pharmalabs unlisted shares?
The process and intermediaries to sell Arch Pharmalabs Unlisted Shares is the same as buying. You can get in touch with your financial intermediary and place a sell order request. This will follow up with a price negotiation process, which is time taking, post which an agreement can be reached. This is when the sell order would actually be executed.
Which is the best platform to buy/sell Arch Pharmalabs unlisted shares?
We at Top10stockbroker.com provide you the feasibility of buying and selling unlisted shares. It is the perfect hub for dealing in Arch Pharmalabs Unlisted Shares, which lets you connect with the right buyer or seller. As per an in-depth comparison with other websites, you would most likely find low and affordable investment options with us.
How to sell Arch Pharmalabs unlisted stocks?
If you are Employees /ex-employees holding the shares, investors/promoters of the Arch Pharmalabs Company, the stock exchange dealers, or any third party holding the unlisted shares. You can choose our platform to sell the Arch Pharmalabs Unlisted Equity Shares at a price range favorable for you. Negotiation is a part of the process.
Can an NRI buy Arch Pharmalabs unlisted shares?
Yes, there is complete relaxation for an NRI for investing in Arch Pharmalabs Unlisted Shares. NRIs can invest in the unlisted shares like resident individuals, but they have to go for a non-repatriable basis. In the case of willingness to opt for a repatriable basis, there is a condition of reporting to RBI.
Why do investors buy unlisted shares?
Unlisted shares are also referred to as Hidden Gems. It is on account of the profit-making potential they contain since investors become part of the company growth. They can fetch investors exponential returns, without having to comply with SEBI Regulations. Other perks are No STT and lower stockbroking charges.
Who sells unlisted or Pre-IPO shares?
Existing shareholders are the perfect medium to buy unlisted shares. They include parties such as Employees, Ex-employees, CEO, Promoters, Private Equity investors, and more. You can get in touch with them and other financial intermediaries through our website Top10stockbroker.com.
How long one should hold to see gains in unlisted shares?
The minimum time limit deemed as likely for exponential gains is 3 years. Accordingly, investors must invest in shares for provided permissible limit for the minimum front. For extended returns, investors can wait for the company to actually go public and grow beyond, the saturation point.
How much ROI to expect from unlisted /Pre-IPO shares?
The ROI is not stagnant or similar for each company. It differs on the basis of Line of business, investment period, managerial capability, and the buying price of the shares. Generally, though there is no guarantee of return on investment, 25% p.a. can be deemed as the likely return.
Most Read Articles